ClinicalTrials.gg
Active, not recruitingNCT07395024Updated Aug 27, 2026

A Study to Learn How Fluconazole, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 in Healthy Adults

A Phase 1 interventional study of Setidegrasib and Fluconazole in Healthy Volunteer, sponsored by Astellas Pharma Global Development, Inc.. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Genes give your body instructions on how to make proteins. Proteins are needed to keep the body working properly. Many types of cancer are caused by changes in certain genes, making them faulty. Some people with solid tumors have a faulty KRAS gene. One such change in the KRAS gene is called a G12D mutation. Researchers are looking for ways to stop the actions of abnormal proteins made from the KRAS G12D mutation.

ASP3082 is thought to replace some of the abnormal proteins made from the faulty KRAS gene. If other medicines are given at the same time as ASP3082, they may affect how the body processes ASP3082.

In this study, fluconazole, itraconazole and carbamazepine are given with ASP3082 in healthy adults. The main aims are to check if fluconazole, itraconazole and carbamazepine affect how the body processes ASP3082. These medicines may affect how the body processes ASP3082 when they are taken at the same time.

This study will have 3 groups of adults. One group will be given fluconazole and ASP3082, the second group will be given carbamazepine and ASP3082, and the third group will be given itraconazole and ASP3082. ASP3082 will be given to people slowly through a tube into the vein (infusion). Fluconazole and carbamazepine will be given as a tablet and itraconazole will be given as a liquid by mouth. People will be given study treatments for about 1 month. They will then return to the clinic about 1 week after they finish study treatment for a final safety check.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • ASP3082
  • Pharmacokinetics
  • Setidegrasib
  • Healthy Volunteers
  • Fluconazole
  • Itraconazole
  • Carbamazepine
03

In context

Lead sponsor

Astellas Pharma Global Development, Inc. is the lead sponsor of 207 studies on the registry; 23 are open to participants now.

Of its 82 completed or terminated interventional studies of FDA-regulated products, 38 (46%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is healthy and has no medical condition based on the physical examination, (ECGs) and protocol-defined clinical laboratory tests at screening or on day -1.
  • Female participant is not pregnant and is not a woman of (WOCBP)
  • Female participant must not be breastfeeding or lactating starting at screening and throughout the period and for 5 half-lives (approximately 28 days after final study intervention administration).
  • Female participant must not donate ova starting at first administration of study intervention and throughout the investigational period and for 3 months after final study intervention administration.
  • Male participant must agree to use with female partner(s) of childbearing potential (including breastfeeding partner) throughout the treatment period and for 3 months after final study intervention administration.
  • Male participant must agree to remain abstinent or use a condom with pregnant partner(s) for the duration of the pregnancy throughout the investigational period and for 3 months after final study intervention administration.
  • Male participant must not donate sperm during the treatment period and for 3 months after final study intervention administration.
  • Participant agrees not to participate in another interventional study while participating in the present study.
  • Participant has a (BMI) range of 18.0 to 32.0 kg/m\^2, inclusive, and weighs at least 50 kg at screening.

Exclusion criteria

Exclusion Criteria:

  • Participant is positive for Human Leukocyte Antigen (HLA) -B15:02 or HLA-A31:01, for Group 2 only.
  • Participant has been pregnant within 6 months prior to screening.
  • Participant has any history or evidence of any cardiovascular, gastrointestinal, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal and/or other major disease.
  • Participant has a history of within 2 years before screening (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy that is considered cured with minimal risk of recurrence).
  • Participant has had major surgery (e.g., requiring general anesthesia) within 90 days before screening, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study or within 5 half-lives (approximately 28 days) after the last dose of study drug administration or end-of-study visit (ESV), whichever is longer.
  • Participant has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection) or fungal (noncutaneous) infection within 28 days prior to day -1.
  • Participant has a history of drug or alcohol abuse according to (5th edition) DSM-5 criteria within 2 years before screening.
  • Participant has a history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmias or torsades de pointes, structural heart disease or a family history of long syndrome.
  • Participant has used any prescribed or nonprescribed drugs (including vitamins, and natural and herbal remedies, e.g., St. John's wort) in the 28 days prior to day -1, except for occasional use of acetaminophen (up to 2 g/day), topical dermatological products (including products) and hormone replacement therapy (HRT).
  • Participant has used any inducer of metabolism (e.g., barbiturates and rifampin) in the 28 days prior to day -1.
  • Participant has received a coronavirus disease 2019 (COVID-19) vaccine within the 14 days prior to day -1 or will have a COVID-19 vaccine dose before the ESV.
  • Participant has received any therapy within 28 days or 5 half-lives, whichever is longer, prior to screening.
  • Participant has any liver test result alkaline phosphatase (ALP), (ALT), aspartate aminotransferase (AST) or total (TBL )) ≥ 1.5 × (ULN ) on day -1.
  • Participant has a creatinine level outside normal limits on day -1.
  • Participant has any of the following conditions on day -1: a mean pulse \< 45 or > 90 bpm, mean systolic blood pressure (SBP ) > 140 mmHg, or mean diastolic blood pressure (DBP) > 90 mmHg (measurements taken in triplicate after participant has been resting in the supine position for at least 5 minutes; pulse measured automatically). If the mean blood pressure exceeds the limits above, 1 additional triplicate measurement may be taken.
  • Participant has a mean corrected QT interval using Fridericia's formula (QTcF ) of > 450 msec on day -1.
  • Participant tests positive for alcohol at screening or on day -1.
  • Participant tests positive for drugs of abuse (amphetamines, barbiturates, benzodiazepines, cocaine and opiates) at screening or on day -1.
  • Participant tests positive for cannabinoids on day -1.
  • Participant has a positive serology test for hepatitis A virus (HAV) antibodies immunoglobulin M (IgM), (HBc) antibodies, hepatitis B surface antigen (HBsAg), virus (HCV) antibodies or antibodies to (HIV ) type 1 and/or type 2 at screening.
  • Participant has a positive rapid COVID-19 antigen test on day -1.
  • Participant has any condition that makes the participant unsuitable for study participation.
  • Participant has a known or suspected to ASP3082 or any components of the formulation used.
  • Participant has a history of smoking > 10 cigarettes (or equivalent amount of tobacco) per day within 3 months prior to day -1 or the participant tests positive for cotinine at screening or day -1.
  • Participant has a history of consuming > 10 units of alcoholic beverages per week within 3 months prior to screening (Note: 1 unit = 12 ounces of beer, 5 ounces of wine, 1.5 ounces of spirits/hard liquor).
  • Participant has used any drugs of abuse (e.g., amphetamines, barbiturates, benzodiazepines, cocaine and/or opiates) within 3 months prior to day -1.
  • Participant has had significant blood loss, donated ≥ 1 unit (450 mL) of whole blood or donated plasma within 7 days prior to day -1 and/or received a transfusion of any blood or blood products within 60 days prior to day -1.
  • Participant has had previous exposure to ASP3082.
  • Participant is an employee of Astellas, the study-related contract research organizations (CROs) or the clinical unit.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Group 1: ASP3082 + Fluconazole

    Participants receive ASP3082 on Days 1 and 15 and fluconazole on Days 8 to 28.

    Drug: Setidegrasib · Drug: Fluconazole

  • Experimental
    Group 2: ASP3082 + Carbamazepine

    Participants receive ASP3082 on Days 1 and 22 and carbamazepine on Days 8 to 28.

    Drug: Setidegrasib · Drug: Carbamazepine

  • Experimental
    Group 3: ASP3082 + Itraconazole

    Participants receive ASP3082 on Days 1 and 15 and itraconazole on Days 8 to 28.

    Drug: Setidegrasib · Drug: Itraconazole

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK) of ASP3082 in plasma: Maximum Concentration (Cmax) in ASP3082

    Cmax will be recorded from the PK plasma samples collected.

    Time frame: Up to 29 days

  2. PK of ASP3082 in plasma: area under the concentration-time curve from time zero to the time of the last measurable concentration (AUClast) in ASP3082

    AUClast will be recorded from the PK plasma samples collected.

    Time frame: Up to 29 days

  3. PK of ASP3082 in plasma: area under the concentration-time curve extrapolated to infinity (AUCinf) in ASP3082

    AUCinf will be calculated from the PK plasma samples collected.

    Time frame: Up to 29 days

  4. PK of ASP3082 in plasma: Cmax in ASP3082+ Fluconazole (FLZ)

    Cmax will be recorded from the PK plasma samples collected.

    Time frame: Up to 29 days

  5. PK of ASP3082 in plasma: AUClast in ASP3082+FLZ

    AUClast will be recorded from the PK plasma samples collected.

    Time frame: Up to 29 days

  6. PK of ASP3082 in plasma: AUCinf in ASP3082+FLZ

    AUCinf will be calculated from the PK plasma samples collected.

    Time frame: Up to 29 days

  7. Ratio of Cmax of ASP3082 and ASP3082+FLZ

    Ratios of Cmax will be calculated from the PK plasma samples collected.

    Time frame: Up to 29 days

  8. Ratio of AUClast of ASP3082 and ASP3082+FLZ

    Ratios of AUClast will be calculated from the PK plasma samples collected.

    Time frame: Up to 29 days

  9. Ratio of AUCinf of ASP3082 and ASP3082+FLZ

    Ratios of AUCinf will be calculated from the PK plasma samples collected.

    Time frame: Up to 29 days

  10. PK of ASP3082 in plasma: Cmax in ASP3082+ Itraconazole (ITZ)

    Cmax will be recorded from the PK plasma samples collected.

    Time frame: Up to 29 days

  11. PK of ASP3082 in plasma: AUClast in ASP3082+ITZ

    AUClast will be recorded from the PK plasma samples collected.

    Time frame: Up to 29 days

  12. PK of ASP3082 in plasma: AUCinf in ASP3082+ITZ

    AUCinf will be calculated from the PK plasma samples collected.

    Time frame: Up to 29 days

  13. Ratio of Cmax of ASP3082 and ASP3082+ITZ

    Ratios of Cmax will be recorded from the PK plasma samples collected.

    Time frame: Up to 29 days

  14. Ratio of AUClast for ASP3082 and ASP3082+ITZ

    Ratios of AUClast will be recorded from the PK plasma samples collected.

    Time frame: Up to 29 days

  15. Ratio of AUCinf for ASP3082 and ASP3082+ITZ

    Ratios of AUCinf will be calculated from the PK plasma samples collected.

    Time frame: Up to 29 days

  16. PK of ASP3082 in plasma: Cmax in ASP3082+ Carbamazepine (CAR)

    Cmax will be recorded from the PK plasma samples collected.

    Time frame: Up to 29 days

  17. PK of ASP3082 in plasma: AUClast in ASP3082+CAR

    AUClast will be recorded from the PK plasma samples collected.

    Time frame: Up to 29 days

  18. PK of ASP3082 in plasma: AUCinf in ASP3082+CAR

    AUCinf will be calculated from the PK plasma samples collected.

    Time frame: Up to 29 days

  19. Ratio of Cmax of ASP3082 and ASP3082+CAR

    Ratios of Cmax will be calculated from the PK plasma samples collected.

    Time frame: Up to 29 days

  20. Ratio of AUClast for ASP3082 and ASP3082+CAR

    Ratios of AUClast will be calculated from the PK plasma samples collected.

    Time frame: Up to 29 days

  21. Ratio of AUCinf for ASP3082 and ASP3082+CAR

    Ratios of AUCinf will be calculated from the PK plasma samples collected.

    Time frame: Up to 29 days

Secondary outcomes

  1. Number of Participants with Adverse Events (AEs)

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. This includes events related to the comparator, if applicable, and events related to the (study) procedures.

    Time frame: Up to 36 days

  2. Number of Participants with laboratory value abnormalities and/or AEs

    Number of participants with potentially clinically significant laboratory values.

    Time frame: Up to 36 days

  3. Number of Participants with vital sign abnormalities and/or AEs

    Number of participants with potentially clinically significant vital sign values.

    Time frame: Up to 36 days

  4. Number of Participants with electrocardiogram (ECG) abnormalities and/or AEs

    Number of participants with potentially clinically significant ECG values.

    Time frame: Up to 36 days

  5. PK of FLZ in plasma: trough concentration (Ctrough)

    Ctrough of FLZ will be recorded from the PK samples collected.

    Time frame: Up to 25 days

  6. PK of CAR in plasma Ctrough

    Ctrough of CAR will be recorded from the PK samples collected.

    Time frame: Up to 28 days

  7. PK of ITZ in plasma Ctrough

    Ctrough of ITZ will be recorded from the PK samples collected.

    Time frame: Up to 25 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for May 2027, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2026
First posted
Feb 9, 2026
StartActual
Feb 3, 2026
Primary completionEst.
May 2, 2027
CompletionEst.
May 2, 2027
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07395024
Responsible party
Sponsor
First posted
Feb 9, 2026
Start date
Feb 3, 2026
Primary completion
May 2, 2027 (estimated)
Completion
May 2, 2027 (estimated)
Last update
Aug 27, 2026

Study contacts

Medical Director
study director · Astellas Pharma Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion